Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Feb;101(1):e43-e49.
doi: 10.1111/aos.15214. Epub 2022 Jul 13.

Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study

Laurent Kodjikian  1   2   3 , Amro Abukhashabah  1   4 , Christine Fardeau  5 , Ramin Tadayoni  6   7 , Antoine Brézin  8 , Stéphane Dumas  9 , Michel Weber  10 , Lorraine Bernard  2   11   12 , Olivier Loria  1   3 , Evelyne Decullier  13 , Laure Huot  2   13 , Thibaud Mathis  1   2   3
Affiliations
Free article
Clinical Trial

Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study

Laurent Kodjikian et al. Acta Ophthalmol. 2023 Feb.
Free article

Abstract

Purpose: To evaluate mean change in best-corrected visual acuity (BCVA) at 52 weeks in patients with inflammatory choroidal neovascularization (CNV) treated with aflibercept.

Methods: We conducted a prospective non-comparative open-label trial. Following one mandatory intravitreal injection of aflibercept, patients were treated under a pro re nata (PRN) dosing regimen with monthly visits.

Results: A total of 19 patients were included, but one presented exclusion criteria; 16 patients were followed for the whole 52-week study, and data for the primary endpoint analysis were available for 14. At baseline, mean BCVA and mean central retinal thickness (CRT) were 64.53 (±19.64) letters and 351.79 (±97.77) μm, respectively. At 52 weeks, the mean change in BCVA was +9.50 (±12.90) letters [95%CI = +2.05-+16.95]. One patient had lost more than 15-letters at 24 weeks, and another one at 52 weeks. CRT change was -62.77 (±100.73) μm at 24 weeks and -66.53 (±97.47) μm at 52 weeks. There was a mean number of 3.56 (±3.29) intravitreal injections at 52 weeks (min = 1; max = 12). No serious ocular adverse events related to the treatment were reported.

Conclusions: Our study shows that aflibercept is clinically effective, both anatomically and functionally in the treatment of inflammatory CNV. Following the first injection, the PRN strategy appears sufficient for treating most choroidal neovessels.

Keywords: aflibercept; anti-vascular endothelial growth factor; inflammatory choroidal neovascularization; intravitreal injection.

PubMed Disclaimer

References

REFERENCES

    1. Adán, A., Mateo, C., Navarro, R., Bitrian, E. & Casaroli-Marano, R.P. (2007) Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina, 27, 1180-1186.
    1. Agarwal, A., Invernizzi, A., Singh, R.B., Foulsham, W., Aggarwal, K., Handa, S. et al. (2018) An update on inflammatory choroidal neovascularization: Epidemiology, multimodal imaging, and management. Journal of Ophthalmic Inflammation and Infection, 8, 13.
    1. Arevalo, J.F., Adan, A., Berrocal, M.H., Espinoza, J.V., Maia, M., Wu, L. et al. (2011) Intravitreal bevacizumab for inflammatory choroidal neovascularization: Results from the Pan-American Collaborative Retina Study Group at 24 months. Retina, 31, 353-363.
    1. Beguier, F., Housset, M., Roubeix, C., Augustin, S., Zagar, Y., Nous, C. et al. (2020) The 10q26 risk haplotype of age-related macular degeneration aggravates subretinal inflammation by impairing monocyte elimination. Immunity, 53, 429-441.
    1. Cunningham, E.T., Pichi, F., Dolz-Marco, R., Freund, K.B. & Zierhut, M. (2020) Inflammatory choroidal neovascularization. Ocular Immunology and Inflammation, 28, 2-6.

Publication types

MeSH terms

Substances

LinkOut - more resources